Siemens Healthineers AG

Q3 group revenue growth was against tough comps of 7.6%. Q3 reported profitability was supported by tariff refunds; excluding those refunds, management said underlying group margin was 15.4%. Imaging margin before tariff refunds was 21.6%; Precision Therapy margin before refunds was 14.1%; Diagnostics margin ex refunds was 3%. Cash flow was over EUR 1 billion, cash conversion was 1.12, net debt fell by around EUR 800 million to around EUR 12 billion, and leverage improved from 3.1x to 2.8x. For FY26, Siemens Healthineers lowered revenue growth guidance to 3.5% to 4% from 4.5% to 5%, raised adjusted EPS guidance to EUR 2.35 to EUR 2.45, expects a tax rate around 23%, and now sees financial income, net at around minus EUR 330 million. For Q4, management expects Imaging to accelerate into the higher single digits, Precision Therapy to continue growing in the higher single digits, and Diagnostics to decline at a mid-single-digit rate.

Bernd Montag emphasized that the quarter validated the company’s market position, pointing to the 1.27 equipment book-to-bill and the two sizable U.S. partnerships with Cleveland Clinic and Vanderbilt Health. He framed the business as a “holistic partner” for hospitals, highlighting demand for productivity, imaging, interventional, radiation oncology, and AI capabilities. His tone was confident on the core businesses and innovation pipeline, but candid that Diagnostics remains structurally challenged and that some Imaging revenue simply moved into Q4.

Jochen Schmitz focused on the segment bridge and guidance mechanics. He said Imaging’s Q3 margin before refunds was 21.6%, Precision Therapy’s was 14.1%, and Diagnostics’ margin ex refunds was 3%, with Diagnostics still pressured by China rebasing and legacy-platform decline. On cash and balance sheet, he highlighted more than EUR 1 billion of cash, 1.12 cash conversion, and leverage down to 2.8x. He also said tariff refunds added about EUR 0.15 to EPS, which is why FY26 EPS guidance was raised even as revenue guidance was lowered.

Analysts pressed on whether the FY27 EPS bridge was conservative and how much it already reflects inflation, separation costs, and China-related headwinds. Management said the bridge is a prudent baseline, that branding fees are not expected in coming years, and that Diagnostics separation costs are not included but would be adjusted if they occur. On China imaging, management said the recently announced centralized bidding changes were anticipated and already baked into plans, and that they will not rely on a China recovery in next year’s guide. They also said Varian remains a high-single-digit growth engine over time, supported by a new platform that should add to backlog and future growth.